Tirzepatide, a once-weekly GIP/GLP-1 receptor agonist, is a medicine used for weight reduction in adults with obesity. A new analysis of the SURMOUNT clinical trials reveals that the medicine ...

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has consistently shown robust body weight reduction in adults ...

The shortage of tirzepatide injection has been resolved after two years of limited availability in the wake of high demand, the FDA said. Tirzepatide is the active ingredient in Mounjaro ...

Jelly Roll’s wife Bunnie XO detailed her harrowing experience taking a small dosage of the weight loss drug tirzepatide. The 44-year-old said she spent the night in the bathroom because of the ...

Tirzepatide, the active ingredient in the diabetes and obesity medications, was declared in shortage in December 2022. The shortage has been attributed to increased demand as interest in GLP-1 ...

MADRID — The majority of patients achieving high rates of glucose control and weight loss in the first year of tirzepatide treatment have sustained success in the second year; however ...

MADRID — Real-world data on tirzepatide (Eli Lilly and Company) from a large population database suggest a safety profile of the drug consistent with that in clinical trials and similar to that ...

Tirzepatide, a dual GIP and GLP-1 receptor agonist, has gained widespread recognition for its effectiveness in promoting substantial weight loss by enhancing metabolic functions and controlling ...

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. Tirzepatide is less expensive and may be more effective. However, the drug is still new, and more research is needed.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Women tended to reap greater weight loss from tirzepatide (Zepbound), a subgroup analysis of the SURMOUNT trials found.